Melanoma prevention using topical PBISe

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Malignant melanoma is a deadly skin cancer with high metastatic potential and drug resistance.
• Deregulated PI3 and mitogen-activated protein (MAP) kinase pathways are implicated in melanoma development and drug resistance.
• Current treatments lack agents to prevent the progression of melanocytic lesions to invasive melanoma.

Purpose of the Study:

• To investigate the potential of a novel selenium-containing compound, PBISe, in preventing melanoma development.
• To determine if PBISe can moderate the PI3 and MAP kinase pathways involved in melanocytic lesion progression.

Main Methods:

• A selenium-containing isosteric analogue, PBISe, was synthesized and tested.
• Topical application of PBISe on laboratory-generated skin and animal skin models.
• Analysis of signaling pathway modulation, cell proliferation, and apoptotic cell death.

Main Results:

• Topical PBISe application retarded melanocytic lesion development by 70-80% in lab-generated skin and approximately 50% in animal skin.
• PBISe decreased Akt3 signaling, leading to increased inhibitory MAP kinase pathway activity.
• The combined pathway modulation resulted in reduced cell proliferation and increased apoptosis.

Conclusions:

• Topically applied PBISe effectively prevents the development of cutaneous melanocytic lesions and invasive melanoma.
• PBISe moderates key signaling pathways, offering a potential therapeutic strategy for melanoma prevention.
• This study highlights PBISe as a promising agent for preventing skin cancer progression.